Skip to main content
Equibles
PODD logo

PODD · Insulet Corp · Metrics

Track PODD — free

Use PODD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PODD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$153.61 +3.93 (+2.63%) At close · Nov 2 Q2 2026 earnings call transcript
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$10.47B
Shares
69.35M
Volume · Nov 2 1.77M Avg daily vol (3M) 1.69M

PODD metrics

111 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$153.61
Market cap
$10.47B

Price action

20 metrics
Price change (1W)
+0.4%
Price change (30D)
+10.4%
Price change (3M)
-9.5%
Price change (6M)
-14.5%
Price change (YTD)
-47.3%
Price change (1Y)
-52.0%
Trailing year
Price change (5Y)
-51.7%
52-week high
$346.36
52-week low
$130.47
Change from 52-week high
-56.8%
Change from 52-week low
+14.7%
Annualized volatility
45.1%
Annualized volatility (3M)
51.3%
Beta
0.3
RSI (14D)
62.3
Price vs SMA 50
+6.2%
Price vs SMA 200
-16.3%
Avg volume (3M)
1.69M
Relative volume
0.7
Average dollar volume
$238.97M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
69.35M

Valuation

12 metrics
P / E (TTM)
28.1
Trailing earnings · reciprocal yield 3.6%
PEG ratio
0.1
EV / revenue
3.6×
reciprocal yield 28.1%
EV / EBITDA
17.7×
reciprocal yield 5.7%
EV / EBIT
21.1×
reciprocal yield 4.7%
P / sales
3.4×
reciprocal yield 29.2%
P / book
7.4
reciprocal yield 13.6%
FCF yield
2.8%
TTM · current market cap
Buyback yield
3.1%
P / FCF
35.6
reciprocal yield 2.8%
P / operating cash flow
20.5
reciprocal yield 4.9%
Earnings yield
3.6%

Historical valuation

8 metrics
P / E historical average (3Y)
74.4×
reciprocal yield 1.3%
P / E historical average (5Y)
2,168.9×
reciprocal yield 0.0%
EV / revenue historical average (3Y)
7.6×
reciprocal yield 13.1%
EV / revenue historical average (5Y)
9.9×
reciprocal yield 10.1%
EV / EBIT historical average (3Y)
52.3×
reciprocal yield 1.9%
EV / EBIT historical average (5Y)
94.2×
reciprocal yield 1.1%
EV / EBITDA historical average (3Y)
39.9×
reciprocal yield 2.5%
EV / EBITDA historical average (5Y)
61.2×
reciprocal yield 1.6%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
3.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
71.1%
Operating margin
16.9%
Trailing 12 months
Net margin
12.3%
Gross profit (TTM)
$2.17B
Operating profit (TTM)
$515.70M
Net income (TTM)
$375.30M
Trailing 12 months
Diluted EPS (TTM)
$5.33
FCF margin
9.6%
Effective tax rate
24.1%

Per share

11 metrics
Revenue per diluted share (TTM)
$43.26
Gross profit per diluted share (TTM)
$30.74
Operating profit per diluted share (TTM)
$7.30
EBITDA per diluted share (TTM)
$8.71
Net income per diluted share (TTM)
$5.31
Operating cash flow per diluted share (TTM)
$7.21
Free cash flow per diluted share (TTM)
$4.16
Capital expenditures per diluted share (TTM)
$3.05
R&D per diluted share (TTM)
$4.90
Stock compensation per diluted share (TTM)
$1.10
Book value per share
$21.53

Growth

11 metrics
Revenue growth YoY
+23.5%
Year over year
Net income growth YoY
+322.2%
Revenue (TTM)
$3.05B
Trailing 12 months
EPS growth YoY
+328.1%
Shares change YoY
-1.8%
Year over year · fewer shares
Revenue CAGR (3Y)
+27.5%
Revenue CAGR (5Y)
+24.5%
EPS CAGR (3Y)
+267.7%
EPS CAGR (5Y)
+103.4%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
26.4%
Return on assets
11.9%
Debt / equity
0.7
Current ratio
2.5
EBITDA (TTM)
$615.00M
Free cash flow (TTM)
$293.70M
Quick ratio
1.8
Interest coverage
8.8
Net debt / EBITDA
0.7
Return on invested capital
21.3%
Trailing 12 months
Net cash
−$413.50M
Latest balance sheet
Cash & equivalents
$534.90M
Total assets
$3.17B
Total debt
$948.40M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$511.20M
Capital expenditures (TTM)
$217.50M
R&D (TTM)
$345.90M
SG&A (TTM)
$1.31B
Stock compensation (TTM)
$77.90M
R&D / revenue
11.3%
Stock compensation / revenue
2.6%

Ownership (13F)

9 metrics
13F filers
739
13F filer change QoQ
-58
Institutional ownership
103.8%
Conviction holders (share of 13F filers)
0.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+0.2%
Holder tenure
15.4
Price vs estimated holder cost
-31.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
22.2%

Short interest

3 metrics
Short interest
8.1%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
$162,217
Insider-sentiment score
77 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1145197 CUSIP 45784P101 13F (30d) 246 filings 223 filers Visit website Investor relations